KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs)
Section snippets
Overview of KIT and PDGFRA mutations in GISTs
The mutation nomenclature used in this review follows recommendations of the Human Genome Variation Society (http://www.hgvs.org). Nucleotide numbering is based on human KIT (X06182) and PDGFRA (M21574) mRNA sequences and dog KIT (AF044249) mRNA from GeneBank (at http://www.ncbi.nlm.nih.gov).
Gain-of-function KIT and PDGFRA mutations are considered to be a major driving force in the pathogenesis of sporadic, nonfamilial GISTs.15, 16 Based on location, these mutations can be divided in two
KIT regulatory domain mutations (exon 9, exon 11)
Nearly all mutations identified in KIT exon 9, a distal part of the KIT-EC domain, represent short, structurally identical duplications of six nucleotides, 1525_1530dupGCCTAT leading to the Ala502_Tyr503dup at the protein level.61, 71, 72, 73 However, more recently, another duplication 1537_1545dupTTTGCATTT leading to the Phe506_Phe508dup at the protein level was reported.72 Two such duplications have been found among 60 (3.3%) KIT exon 9 mutant GISTs identified at AFIP. An Ala502_Phe506dup
KIT enzymatic domain mutations (exon 13, exon 14, exon 17)
A 1945A>G point mutation resulting in Lys642Glu substitution at the protein level was initially reported in two GISTs negative for KIT-JM mutation.39 This mutation affects exon 13 encoding proximal part of the KIT-TK1 (ATP-binding domain) and has been found to lead to constitutive KIT tyrosine phosphorylation.39 A subsequent study of a relatively large number of GISTs from different locations estimated the frequency of this mutation to be no higher than 2.5%.40, 56
Recent studies on GISTs, based
PDGFRA regulatory domain mutations (exon 12)
Mutations in PDGFRA-JM domain are relatively rare and represent approximately 6% to 9% of all PDGFRA mutations reported in GISTs.42, 43 These mutations consist of point mutations, deletions, deletion–insertions, and insertions.16, 42, 43 The most common is 1821T>A leading to Val561Asp substitution at the protein level followed in frequency by deletion/deletion insertions and insertions. In general, these mutations affect the vicinity of codon 561 or a region located immediately 3′ to this codon.
PDGFRA enzymatic domain mutation (exon 14, exon 18)
An Asn659Lys in PDGFRA exon 14 was first reported in KIT-negative gastric GIST.116 Subsequently, 2 more cases with such missense mutations were reported,43 and a study based on 200 GISTs negative for KIT exon 9, 11, 13, and 17 and PDGFRA exon 12 and 18 mutations identified 11 PDGFRA exon 14 mutations.42 A majority of these 11 mutations represented 2125C>A and 2125C>G leading to Asn659Lys at the protein level. However, in 3 cases, variant point mutations, 2123A>T leading to Asn659Tyr, were found
KIT and PDGFRA mutational status in NF1 and pediatric and Carney triad GISTs
Several studies evaluated KIT and PDGFRA mutation status in GISTs from neurofibromatosis type 1 (NF1) patients.118, 119, 120, 121, 122, 123, 124 In general, no mutations in GIST-specific KIT or PDGFRA mutational “hot spots” have been found in multiple tumors from NF1 patients. However, one study identified two KIT (Pro627Leu and Ile653Thr) and two PDGFRA (Pro589Lys and Arg822Ser) missense mutations in two separate lesions from two patients.120 These mutations might be random genetic events
Frequency of KIT and PDGFRA mutations
Frequency of the KIT and PDGFRA mutations differs between the studies. Several factors contribute to these differences. First, KIT and PDGFRA mutations are unequally distributed among GISTs. For example, studies with a large number of intestinal GISTs will show a higher frequency of KIT exon 9 mutants, whereas studies with a higher number of gastric epithelioid tumors will show a lower number of KIT-mutants and a higher number of PDGFRA-mutants. Moreover, studies based on material from cancer
Prognostic value of KIT and PDGFRA mutations
The prognostic value of KIT and PDGFRA mutations in primary tumors is controversial. Some of the early studies reported that KIT exon 11 mutations are more common in large and malignant GISTs,54, 55 and adverse prognostic significance of such mutations was suggested.54, 55, 90 However, others have also shown these mutations in diminutive, clinically indolent incidental tumors.64
More recent studies, based on larger numbers of cases and evaluating both KIT and PDGFRA mutational status, indicated
Primary KIT and PDGFRA mutations and imatinib-based treatment
Imatinib mesylate, STI571, commercially known as Gleevec/Glivec™ (http://www.novartis.com) that inhibits KIT, PDGFRA, and ABL tyrosine kinases has been used in the treatment of clinically advanced, unresectable, and metastatic GISTs.135, 136 More recently, sunitinib malate, also known as SU11248 (http://www.pfizer.com), that inhibits KIT and some other tyrosine kinases has also been approved on the same indication.137, 138
A great majority of patients benefit from imatinib mesylate-based
Secondary KIT and PDGFRA mutations acquired during imanitib-based treatment
An acquired resistance has been reported during imatinib-based treatment and linked to secondary KIT or PDGFRA mutations.66, 142 Initial studies showed that secondary KIT mutations occur in the allele that harbors primary gain-of-function KIT mutation and in a great majority of cases represents missense point mutation affecting the first or second tyrosine kinase domain (Figure 9).66, 89, 143, 144, 145 Subsequently, polyclonal evolution of multiple secondary KIT mutations has also been reported.
References (147)
Regulation and targets of receptor tyrosine kinases
Eur J Cancer
(2002)Role of KIT and platelet-derived growth factor receptors as oncoproteins
Semin Oncol
(2004)- et al.
Identification of a ligand for the c-kit protooncogene
Cell
(1990) - et al.
Stem cell factor is encoded at the S1 locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor
Cell
(1990) - et al.
Classes of c-KIT activating mutations: proposed mechanisms of action and implications in disease classification and therapy
Leuk Res
(2001) - et al.
Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations
Human Pathol
(2002) - et al.
Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit
Exp Hematol
(1999) - et al.
Clustering of activating mutations in c-KIT’s juxtamembrane coding region in canine mast cell neoplasms
J Invest Dermatol
(1999) - et al.
A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors
Gastroenterology
(1998) - et al.
Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene
Gastroenterology
(2001)
Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of KIT gene
Gastroenterology
PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor
Gastroenterology
Frequent c-KIT gene mutations not only in gastrointestinal stromal tumors but also in interstitial cells of Cajal in surrounding normal tissue
Cancer Letter
KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors
Am J Pathol
Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumorsA study of two hundred cases
Am J Pathol
A great majority of GISTs with PDGFRA mutations represents gastric tumors of low or no malignant potential
Lab Invest
GISTs with PDGFRA exon 14 mutations represent subset of clinically favorable gastric tumors with epithelioid morphology
Lab Invest
Activating c-kit gene mutations in human germ cell tumors
Am J Pathol
Primary mediastinal seminomas: evidence of single and multiple KIT mutations
Lab Invest
KIT mutations are common in testicular seminomas
Am J Pathol
Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis
Gastroenterology
Mutations in exon 11 of c-kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas
Am J Pathol
The complexity of KIT gene mutations and chromosome rearrangements and their clinical correlation in gastrointestinal stromal (pacemaker cell) tumors
Am J Pathol
Clinicopathologic, phenotypic, and genotypic characteristics of gastrointestinal mesenchymal tumors
Clin Gastroenterol Hepatol
A high frequency of sequence alterations is due to formalin fixation of archival specimens
Am J Pathol
KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size
Am J Pathol
Mechanisms of resistence to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants
Gastroentereology
Expression of isoforms of the human receptor tyrosine kinase c-kit in leukemic cell lines and acute myeloid leukemia
Blood
Apparent KIT Ser715 deletion in GISTs mRNA is not detectable in genomic DNA and represents a previously known splice variant of KIT transcript
Am J Pathol
KIT 1530ins6 mutation defines a subset of predominantly malignant gastrointestinal stromal tumors of intestinal origin
Human Pathol
Association of platelet-derived growth factor receptor α mutations with gastric primary site and epithelioid or mixed cell morphology in gastrointestinal stromal tumors
J Mol Diagn
Differential expression of KIT/PDGFRA mutant isoforms in epithelioid and mixed variants of gastrointestinal stromal tumors depends predominantly on the tumor site
Mod Pathol
Gastrointestinal stromal tuomours (GISTs): a clinicopathological and molecular study of 66 cases
Pathology
Patterns of gene amplification in gastrointestinal stromal tumors (GIST)
Lab Invest
Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis
Gastroenterology
c-kit mutations in gastrointestinal stromal tumors occur preferentially in the spindle rather than in the epithelioid cell variant
Mod Pathol
KIT gene deletion at the intron 10-exon 11boundry in GI stromal tumors
J Mol Diag
c-kit mutations in gastrointestinal stromal tumours
Pathology
BRAF and c-kit gene copy number in mutation positive malignant melanoma
Hum Pathol
A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family
Nature
Isolation a novel receptor cDNA establishes the existence of two PDGF receptor genes
Science
Tandem linkage of human CSF-1 receptor (c-fms) and PDGF receptor genes
Cell
Human PDGFA receptor gene maps to the same region on chromosome 4 as the KIT oncogene
Genes Chromosomes Cancer
Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand
EMBO J
The protooncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus
Nature
Activation of the human c-kit product by ligand-induced dimerization mediates circular actin reorganization and chemotaxis
EMBO J
Requirement of c-kit for development of intestinal pacemaker system
Development
Interspecies molecular chimeras of kit helps define the binding site of the stem cell factor
Mol Cell Biol
Gastrointestinal peristalsis: joint action of enteric nerves, smooth muscle, and interstitial cells of Cajal
Microsc Res Tech
Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors
Science
Cited by (241)
Inflammatory fibroid polyp: A series of 29 cases and a systematic review of the literature
2023, Human Pathology ReportsExploring Perforated Jejunal GIST: A Rare Case Report and Review of Molecular and Clinical Literature
2024, Current Issues in Molecular BiologyConsistency between Primary Uterine Corpus Malignancies and Their Corresponding Patient-Derived Xenograft Models
2024, International Journal of Molecular SciencesNeurofibromatosis- and schwannomatosis- associated tumors: Approaches to genetic testing and counseling considerations
2023, American Journal of Medical Genetics, Part A
The opinions and assertions contained herein are the expressed views of the authors and are not to be construed as official or reflecting the views of the Departments of the Army or Defense.